Product Description
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bulgaria | Germany | India | Ireland | Italy | New Zealand | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Shandong University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2019_EOS_001 | N/A |
Recruiting |
Neonatal Sepsis |
2025-10-01 |